VLA-1601 is under clinical development by Valneva and currently in Phase I for Zika Virus Infections. According to GlobalData, Phase I drugs for Zika Virus Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VLA-1601 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VLA-1601 overview
VLA-1601 is under development for the prevention of Zika virus infections. It is administered through intramuscular route. The therapeutic candidate is an inactivated, whole Zika virus (ZIKV) vaccine adsorbed on aluminum hydroxide (alum). It is developed based on IXIARO (JESPECT) platform.
Valneva overview
Valneva is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company’s products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of Lyme disease, Zika virus, Chikungunya and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.
For a complete picture of VLA-1601’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
